000403 派林生物
已收盘 03-06 15:00:00
资讯
新帖
简况
派林生物最新公告：全资子公司获得人凝血酶药品注册临床试验受理通知书
证券之星 · 02-05
派林生物最新公告：全资子公司获得人凝血酶药品注册临床试验受理通知书
派林生物(000403.SZ)子公司获人凝血因子IX药品注册上市许可
智通财经 · 02-04
派林生物(000403.SZ)子公司获人凝血因子IX药品注册上市许可
每周股票复盘：派林生物（000403）控股权拟变更为中国生物
证券之星 · 01-02
每周股票复盘：派林生物（000403）控股权拟变更为中国生物
【机构调研记录】华泰柏瑞基金调研派林生物
证券之星 · 2025-12-25
【机构调研记录】华泰柏瑞基金调研派林生物
派林生物（000403）披露全资子公司获得药物临床试验批准通知书，12月24日股价上涨6.86%
证券之星 · 2025-12-24
派林生物（000403）披露全资子公司获得药物临床试验批准通知书，12月24日股价上涨6.86%
12月24日派林生物涨6.86%，鹏华安庆混合A基金重仓该股
证券之星 · 2025-12-24
12月24日派林生物涨6.86%，鹏华安庆混合A基金重仓该股
派林生物(000403.SZ)：静注人免疫球蛋白(pH4)获得药物临床试验批
智通财经 · 2025-12-23
派林生物(000403.SZ)：静注人免疫球蛋白(pH4)获得药物临床试验批
派林生物：公司截止2025年11月28日股东人数为34061户
证券之星 · 2025-12-10
派林生物：公司截止2025年11月28日股东人数为34061户
派林生物：公司截止10月31日股东人数33313户
证券之星 · 2025-12-08
派林生物：公司截止10月31日股东人数33313户
派林生物（000403）披露召开2025年第四次临时股东大会通知，12月05日股价上涨0.89%
证券之星 · 2025-12-05
派林生物（000403）披露召开2025年第四次临时股东大会通知，12月05日股价上涨0.89%
每周股票复盘：派林生物（000403）变更募资用途获通过
证券之星 · 2025-11-16
每周股票复盘：派林生物（000403）变更募资用途获通过
派林生物（000403）披露变更募集资金用途及节余资金补充流动资金议案获股东大会通过，11月13日股价上涨1.05%
证券之星 · 2025-11-13
派林生物（000403）披露变更募集资金用途及节余资金补充流动资金议案获股东大会通过，11月13日股价上涨1.05%
股市必读：派林生物（000403）11月7日董秘有最新回复
证券之星 · 2025-11-10
股市必读：派林生物（000403）11月7日董秘有最新回复
派林生物：截止2025年9月30日股东人数32041户
证券之星 · 2025-11-07
派林生物：截止2025年9月30日股东人数32041户
派林生物：控制权转让事项推进进展顺利
证券之星 · 2025-11-07
派林生物：控制权转让事项推进进展顺利
每周股票复盘：派林生物（000403）Q3净利降43.74%
证券之星 · 2025-11-02
每周股票复盘：派林生物（000403）Q3净利降43.74%
派林生物（000403）2025年三季报简析：净利润同比下降34.19%，存货明显上升
证券之星 · 2025-10-30
派林生物（000403）2025年三季报简析：净利润同比下降34.19%，存货明显上升
图解派林生物三季报：第三季度单季净利润同比下降43.74%
证券之星 · 2025-10-29
图解派林生物三季报：第三季度单季净利润同比下降43.74%
派林生物（000403）披露变更募集资金用途及节余资金补流公告，10月28日股价上涨0.06%
证券之星 · 2025-10-28
派林生物（000403）披露变更募集资金用途及节余资金补流公告，10月28日股价上涨0.06%
46.99亿入主派林生物 国药系血液制品版图再扩张
新浪证券 · 2025-09-19
46.99亿入主派林生物 国药系血液制品版图再扩张
加载更多
公司概况
公司名称：
派斯双林生物制药股份有限公司
所属行业：
医药制造业
上市日期：
1996-06-28
主营业务：
派斯双林生物制药股份有限公司的主营业务是血液制品的研究、开发、生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白（pH4）、人免疫球蛋白、乙型肝炎人免疫球蛋白、破伤风人免疫球蛋白、狂犬病人免疫球蛋白、人凝血因子Ⅷ、人凝血酶原复合物、人血白蛋白、静注人免疫球蛋白（pH4）、冻干静注人免疫球蛋白（pH4）、人免疫球蛋白、人纤维蛋白原、乙型肝炎人免疫球蛋白、破伤风人免疫球蛋白、狂犬病人免疫球蛋白、静注乙型肝炎人免疫球蛋白（pH4）。
发行价格：
3.78
{"stockData":{"symbol":"000403","market":"SZ","secType":"STK","nameCN":"派林生物","latestPrice":14.03,"timestamp":1772780613000,"preClose":13.89,"halted":0,"volume":6945229,"delay":0,"changeRate":0.0101,"floatShares":941000000,"shares":950000000,"eps":0.589,"marketStatus":"已收盘","change":0.14,"latestTime":"03-06 15:00:00","open":13.85,"high":14.06,"low":13.8,"amount":97113400,"amplitude":0.0187,"askPrice":14.04,"askSize":210,"bidPrice":14.03,"bidSize":693,"shortable":0,"etf":0,"ttmEps":0.589,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773019800000},"marketStatusCode":5,"adr":0,"adjPreClose":13.89,"symbolType":"stock","openAndCloseTimeList":[[1772760600000,1772767800000],[1772773200000,1772780400000]],"highLimit":15.28,"lowLimit":12.5,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":950397386,"isCdr":false,"pbRate":1.64,"roa":"--","peRate":23.820034,"roe":"4.45%","epsLYR":1.02,"committee":-0.159589,"marketValue":13334000000,"turnoverRate":0.0074,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-03-09。","floatMarketCap":13198000000},"requestUrl":"/m/hq/s/000403","defaultTab":"news","newsList":[{"id":"2609976327","title":"派林生物最新公告：全资子公司获得人凝血酶药品注册临床试验受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2609976327","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609976327?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:57","pubTimestamp":1770281854,"startTime":"0","endTime":"0","summary":"派林生物公告称，公司全资子公司广东双林收到国家药品监督管理局核准签发的人凝血酶药品注册临床试验《受理通知书》。目前国内拥有该产品上市批件的企业包括华兰生物和上海莱士。公司获得受理通知书对当期业绩不会产生影响，但长期将丰富产品线，优化产品结构，提升原料血浆综合利用率和盈利能力。药品研发具有不确定性，公司将积极推进并及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500026870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000403","BK0071"],"gpt_icon":0},{"id":"2608356918","title":"派林生物(000403.SZ)子公司获人凝血因子IX药品注册上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2608356918","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608356918?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:22","pubTimestamp":1770193364,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派林生物(000403.SZ)公告，公司全资子公司广东双林生物制药有限公司(称“广东双林”)收到国家药品监督管理局核准签发的人凝血因子IX药品注册上市许可《受理通知书》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401534.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000403","IX","BK0239","BK0071","BK4184"],"gpt_icon":0},{"id":"2600035299","title":"每周股票复盘：派林生物（000403）控股权拟变更为中国生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2600035299","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600035299?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:12","pubTimestamp":1767291131,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，派林生物报收于14.14元，较上周的13.39元上涨5.6%。本周关注点公司公告汇总：派林生物控股股东签署补充协议，控制权拟变更为中国生物，最终截止日延长至2026年6月30日。本次权益变动涉及胜帮英豪向中国生物转让公司21.03%股份，若完成，中国生物将成为公司控股股东，中国医药集团有限公司将成为实际控制人。本次交易尚需取得深交所合规性确认及中登公司过户登记等审批，存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0071","BK0239"],"gpt_icon":0},{"id":"2594928868","title":"【机构调研记录】华泰柏瑞基金调研派林生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2594928868","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594928868?lang=zh_cn&edition=full","pubTime":"2025-12-25 08:11","pubTimestamp":1766621507,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及12月24日披露的机构调研信息，华泰柏瑞基金近期对1家上市公司进行了调研，相关名单如下：1）派林生物 调研纪要：2025年前三季度，公司营收与净利润同比下降，系广东双林和派斯菲科推进二期扩产所致。华泰柏瑞基金成立于2004年，截至目前，资产管理规模7807.03亿元，排名15/212；资产管理规模3248.08亿元，排名19/212；管理公募基金数326只，排名23/212；旗下公募基金经理44人，排名26/212。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500004399.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","BK0239","000403"],"gpt_icon":0},{"id":"2593475897","title":"派林生物（000403）披露全资子公司获得药物临床试验批准通知书，12月24日股价上涨6.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593475897","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593475897?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:46","pubTimestamp":1766569587,"startTime":"0","endTime":"0","summary":"截至2025年12月24日收盘，派林生物报收于14.01元，较前一交易日上涨6.86%，最新总市值为133.15亿元。该股当日开盘13.14元，最高14.3元，最低13.08元，成交额达5.38亿元，换手率为4.12%。公司近日发布公告称，其全资子公司广东双林生物制药有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意其开展静注人免疫球蛋白生产工艺变更后的临床试验。后续需按批件要求完成临床研究，并经国家药品监督管理局审评审批后方可上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400028756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0071","000403"],"gpt_icon":0},{"id":"2593061422","title":"12月24日派林生物涨6.86%，鹏华安庆混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2593061422","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593061422?lang=zh_cn&edition=full","pubTime":"2025-12-24 15:35","pubTimestamp":1766561743,"startTime":"0","endTime":"0","summary":"证券之星消息，12月24日派林生物涨6.86%，收盘报14.01元，换手率4.12%，成交量38.76万手，成交额5.38亿元。融资融券方面近5日融资净流出483.61万，融资余额减少；融券净流出3.96万，融券余额减少。重仓派林生物的公募基金请见下表：根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为鹏华基金的鹏华安庆混合A。鹏华安庆混合A目前规模为1.98亿元，最新净值1.3328，较上一交易日下跌0.11%，近一年上涨10.11%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400019580.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0071","BK0239"],"gpt_icon":0},{"id":"2593249542","title":"派林生物(000403.SZ)：静注人免疫球蛋白(pH4)获得药物临床试验批","url":"https://stock-news.laohu8.com/highlight/detail?id=2593249542","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593249542?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:33","pubTimestamp":1766482425,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派林生物(000403.SZ)发布公告，近日，公司之全资子公司广东双林生物制药有限公司(以下简称“广东双林”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》(通知书编号：2025LP03518)，同意广东双林开展静注人免疫球蛋白(pH4)生产工艺变更后的临床试验。本次静注人免疫球蛋白(pH4)生产工艺由传统的低温乙醇蛋白分离法变更为国际主流的辛酸沉淀及多步层析精制纯化工艺，在产品质量、病毒安全性等方面，特别是产品收率方面有显著的提高，同时有助于提升临床用药安全性及便捷性，使国内产品工艺水平与国际接轨，将进一步提升公司第四代静注人免疫球蛋白产品市场竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"派林生物(000403.SZ)：静注人免疫球蛋白(pH4)获得药物临床试验批","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0071","BK0239","000403"],"gpt_icon":0},{"id":"2590530410","title":"派林生物：公司截止2025年11月28日股东人数为34061户","url":"https://stock-news.laohu8.com/highlight/detail?id=2590530410","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590530410?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:09","pubTimestamp":1765354145,"startTime":"0","endTime":"0","summary":"证券之星消息，派林生物(000403)12月10日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的公司董秘：您好！请问截止11月30日，公司股东人数是多少？谢谢！派林生物回复：尊敬的投资者，您好！公司截止2025年11月28日股东人数为34061户。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000021045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000403","BK0071"],"gpt_icon":0},{"id":"2589380401","title":"派林生物：公司截止10月31日股东人数33313户","url":"https://stock-news.laohu8.com/highlight/detail?id=2589380401","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589380401?lang=zh_cn&edition=full","pubTime":"2025-12-08 15:57","pubTimestamp":1765180635,"startTime":"0","endTime":"0","summary":"证券之星消息，派林生物(000403)12月08日在投资者关系平台上答复投资者关心的问题。投资者提问：请问10月31日的股东人数是多少，谢谢派林生物回复：尊敬的投资者，您好！公司截止10月31日股东人数33313户。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800013469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0071","000403"],"gpt_icon":0},{"id":"2589893211","title":"派林生物（000403）披露召开2025年第四次临时股东大会通知，12月05日股价上涨0.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589893211","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589893211?lang=zh_cn&edition=full","pubTime":"2025-12-05 17:46","pubTimestamp":1764927992,"startTime":"0","endTime":"0","summary":"截至2025年12月5日收盘，派林生物报收于14.68元，较前一交易日上涨0.89%，最新总市值为139.52亿元。该股当日开盘14.59元，最高14.68元，最低14.3元，成交额达1.02亿元，换手率为0.75%。公司近日发布公告，宣布将于2025年12月22日召开2025年第四次临时股东大会，会议采取现场投票与网络投票相结合的方式。股权登记日为2025年12月15日。本次股东大会将审议《关于修订<公司章程>及部分治理制度的议案》及其子议案共9项。中小投资者表决情况将单独计票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500027684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","000403","BK0239"],"gpt_icon":0},{"id":"2583765116","title":"每周股票复盘：派林生物（000403）变更募资用途获通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2583765116","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583765116?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:41","pubTimestamp":1763235672,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，派林生物报收于16.3元，较上周的16.05元上涨1.56%。派斯双林生物制药股份有限公司于2025年11月13日召开2025年第三次临时股东大会，审议通过了《关于变更募集资金用途的议案》和《关于部分募投项目节余募集资金永久补充流动资金的议案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","000403","BK0239"],"gpt_icon":0},{"id":"2583599172","title":"派林生物（000403）披露变更募集资金用途及节余资金补充流动资金议案获股东大会通过，11月13日股价上涨1.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583599172","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583599172?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:33","pubTimestamp":1763044400,"startTime":"0","endTime":"0","summary":"截至2025年11月13日收盘，派林生物报收于16.32元，较前一交易日上涨1.05%，最新总市值为155.1亿元。该股当日开盘16.15元，最高16.35元，最低16.09元，成交额达1.18亿元，换手率为0.77%。近日，派斯双林生物制药股份有限公司召开2025年第三次临时股东大会，审议通过了《关于变更募集资金用途的议案》和《关于部分募投项目节余募集资金永久补充流动资金的议案》。两项议案均获得高票通过，反对和弃权比例较低。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300042456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0071","000403"],"gpt_icon":0},{"id":"2582818170","title":"股市必读：派林生物（000403）11月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2582818170","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582818170?lang=zh_cn&edition=full","pubTime":"2025-11-10 02:04","pubTimestamp":1762711459,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，派林生物报收于16.05元，上涨1.84%，换手率1.05%，成交量9.88万手，成交额1.58亿元。董秘最新回复投资者： 请问截止9月30日的股东户数董秘： 尊敬的投资者，您好！公司截止2025年9月30日股东人数32041户。以便广大投资者更有信心董秘： 尊敬的投资者，您好！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000000816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","BK0239","000403"],"gpt_icon":0},{"id":"2581402193","title":"派林生物：截止2025年9月30日股东人数32041户","url":"https://stock-news.laohu8.com/highlight/detail?id=2581402193","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581402193?lang=zh_cn&edition=full","pubTime":"2025-11-07 11:33","pubTimestamp":1762486415,"startTime":"0","endTime":"0","summary":"证券之星消息，派林生物(000403)11月07日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！请问截止9月30日公司股东人数多少？目前在研管线及进展如何？以便广大投资者更有信心派林生物回复：尊敬的投资者，您好！公司截止2025年9月30日股东人数32041户；公司目前积极推进第四代静丙、九因子、静丙（PH4）工艺变更、八因子等项目研发，具体进展详见公司定期报告等公告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700014662.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0071","000403"],"gpt_icon":0},{"id":"2581931021","title":"派林生物：控制权转让事项推进进展顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2581931021","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581931021?lang=zh_cn&edition=full","pubTime":"2025-11-07 11:33","pubTimestamp":1762486414,"startTime":"0","endTime":"0","summary":"证券之星消息，派林生物(000403)11月07日在投资者关系平台上答复投资者关心的问题。投资者提问：您好！公司于2025年9月10日公告了关于控股股东签署《股份转让协议》暨公司控制权拟发生变更的进展公告，请问，目前项目推进到哪里了派林生物回复：尊敬的投资者，您好！公司控制权转让事项正在推进法律法规要求的批准程序，控制权转让事项推进进展顺利，请您关注公司后续进展公告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700014653.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0071","000403"],"gpt_icon":0},{"id":"2580472800","title":"每周股票复盘：派林生物（000403）Q3净利降43.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580472800","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580472800?lang=zh_cn&edition=full","pubTime":"2025-11-02 06:28","pubTimestamp":1762036091,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，派林生物报收于15.74元，较上周的16.37元下跌3.85%。业绩披露要点：2025年第三季度归母净利润1.21亿元，同比下降43.74%。股本股东变化股东户数变动截至2025年9月30日，派林生物股东户数为3.2万户，较6月30日增加5109.0户，增幅18.97%。业绩披露要点财务报告派林生物2025年三季报显示，主营收入16.18亿元，同比下降14.4%；归母净利润3.57亿元，同比下降34.19%；扣非净利润3.23亿元，同比下降35.1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001335.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","BK0239","000403"],"gpt_icon":0},{"id":"2579130196","title":"派林生物（000403）2025年三季报简析：净利润同比下降34.19%，存货明显上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2579130196","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579130196?lang=zh_cn&edition=full","pubTime":"2025-10-30 06:22","pubTimestamp":1761776528,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期派林生物发布2025年三季报。截至本报告期末，公司营业总收入16.18亿元，同比下降14.4%，归母净利润3.57亿元，同比下降34.19%。按单季度数据看，第三季度营业总收入6.32亿元，同比下降16.23%，第三季度归母净利润1.21亿元，同比下降43.74%。本报告期派林生物存货明显上升，存货同比增幅达51.94%。去年的净利率为28.07%，算上全部成本后，公司产品或服务的附加值高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000005337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403"],"gpt_icon":0},{"id":"2579799585","title":"图解派林生物三季报：第三季度单季净利润同比下降43.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579799585","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579799585?lang=zh_cn&edition=full","pubTime":"2025-10-29 02:54","pubTimestamp":1761677646,"startTime":"0","endTime":"0","summary":"证券之星消息，派林生物2025年三季报显示，公司主营收入16.18亿元，同比下降14.4%；归母净利润3.57亿元，同比下降34.19%；扣非净利润3.23亿元，同比下降35.1%；其中2025年第三季度，公司单季度主营收入6.32亿元，同比下降16.23%；单季度归母净利润1.21亿元，同比下降43.74%；单季度扣非净利润1.09亿元，同比下降46.09%；负债率16.25%，投资收益1610.06万元，财务费用-2766.96万元，毛利率46.32%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900003248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403"],"gpt_icon":0},{"id":"2578658879","title":"派林生物（000403）披露变更募集资金用途及节余资金补流公告，10月28日股价上涨0.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578658879","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578658879?lang=zh_cn&edition=full","pubTime":"2025-10-28 22:23","pubTimestamp":1761661436,"startTime":"0","endTime":"0","summary":"截至2025年10月28日收盘，派林生物报收于16.1元，较前一交易日上涨0.06%，最新总市值为153.01亿元。该股当日开盘16.09元，最高16.12元，最低16.03元，成交额达6756.87万元，换手率为0.45%。近日，派斯双林生物制药股份有限公司发布第十届监事会第十二次会议决议公告。公告显示，公司于2025年10月27日以通讯方式召开会议，应出席监事5人，实际出席5人。上述议案均获得5票同意、0票反对、0票弃权。相关公告已披露于《证券时报》《上海证券报》和巨潮资讯网。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800043130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0071","BK0239"],"gpt_icon":0},{"id":"2568562259","title":"46.99亿入主派林生物 国药系血液制品版图再扩张","url":"https://stock-news.laohu8.com/highlight/detail?id=2568562259","media":"新浪证券","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568562259?lang=zh_cn&edition=full","pubTime":"2025-09-19 17:15","pubTimestamp":1758273300,"startTime":"0","endTime":"0","summary":"近日，派林生物发布公告，控股股东胜帮英豪与中国生物技术股份有限公司签署《股份转让协议》，拟将其持有的公司21.03%股份、合计近2亿股，以总价46.99亿元转让给中国生物。交易完成后，中国生物将成为派林生物新任控股股东，实际控制人变更为中国医药集团有限公司。这也是自今年6月中国生物拟入主消息公布以来，该事项迎来的实质性进展。交易完成后，中国生物血浆资源总量将占全国30%以上，掌握9个血液制品牌照，行业控制力显著增强。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-09-19/doc-infqzkhi3058813.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","000403","BK0071"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772963512593,"stockEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":0.0286},{"period":"3month","weight":-0.0443},{"period":"6month","weight":-0.2206},{"period":"1year","weight":-0.1186},{"period":"ytd","weight":0.0248}],"compareEarnings":[{"period":"1week","weight":-0.0093},{"period":"1month","weight":0.0054},{"period":"3month","weight":0.0567},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.2198},{"period":"ytd","weight":0.0391}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"派斯双林生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"34061人(较上一季度增加2.25%)","perCapita":"27618股","listingDate":"1996-06-28","address":"山西省太原市晋源区长兴南街8号阳光城环球金融中心3004室","registeredCapital":"95039万元","survey":" 派斯双林生物制药股份有限公司的主营业务是血液制品的研究、开发、生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白（pH4）、人免疫球蛋白、乙型肝炎人免疫球蛋白、破伤风人免疫球蛋白、狂犬病人免疫球蛋白、人凝血因子Ⅷ、人凝血酶原复合物、人血白蛋白、静注人免疫球蛋白（pH4）、冻干静注人免疫球蛋白（pH4）、人免疫球蛋白、人纤维蛋白原、乙型肝炎人免疫球蛋白、破伤风人免疫球蛋白、狂犬病人免疫球蛋白、静注乙型肝炎人免疫球蛋白（pH4）。","listedPrice":3.78},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"派林生物(000403)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供派林生物(000403)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"派林生物,000403,派林生物股票,派林生物股票老虎,派林生物股票老虎国际,派林生物行情,派林生物股票行情,派林生物股价,派林生物股市,派林生物股票价格,派林生物股票交易,派林生物股票购买,派林生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"派林生物(000403)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供派林生物(000403)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}